Salarius Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

* Salarius Pharmaceuticals (NASDAQ:SLRX [https://seekingalpha.com/symbol/SLRX]) on Tuesday said it has received notification from Nasdaq that it has regained compliance with the Minimum Bid Price Requirement.
* As disclosed on August 27, Salarius has until October 20, 2025 to regain compliance with the listing rule.
* On January 13, 2025, Salarius announced it had entered into a definitive merger agreement for a business combination with Decoy Therapeutics. Under the agreement, Decoy will merge with a wholly owned subsidiary of Salarius, subject to the closing conditions set forth in the agreement. The newly formed company will be named Decoy Therapeutics.
* SLRX +7.52% premarket to $5.0.
* Source: Press Release [https://seekingalpha.com/pr/20225697-salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement]

MORE ON SALARIUS PHARMACEUTICALS

* Salarius Pharmaceuticals granted additional extension to regain Nasdaq compliance [https://seekingalpha.com/news/4467178-salarius-pharmaceuticals-granted-additional-extension-to-regain-nasdaq-compliance]
* Financial information for Salarius Pharmaceuticals [https://seekingalpha.com/symbol/SLRX/income-statement]